{
    "clinical_study": {
        "@rank": "41913", 
        "acronym": "ADD", 
        "arm_group": [
            {
                "arm_group_label": "Pioglitazone 15 mg", 
                "arm_group_type": "Experimental", 
                "description": "Pioglitazone 15 mg tablets, orally, once daily, and metformin and sulfonylurea will be administered according to the prescribing information of the approved Korean label, for up to 24 weeks."
            }, 
            {
                "arm_group_label": "Pioglitazone 30 mg", 
                "arm_group_type": "Experimental", 
                "description": "Pioglitazone 30 mg tablets, orally, once daily, and metformin and sulfonylurea will be administered according to the prescribing information of the approved Korean label, for up to 24 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy of pioglitazone 30 mg as compared with\n      pioglitazone 15 mg on glycemic control as when used in patients with inadequately controlled\n      type 2 diabetes mellitus treated with fixed combinations of metformin and sulfonylurea."
        }, 
        "brief_title": "Efficacy of Pioglitazone in Patients With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type II Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "The drug being tested in this study is called pioglitazone. Pioglitazone is being tested to\n      treat glycemic control in adults with inadequately controlled type 2 diabetes mellitus. This\n      study will look at glycemic control in people who take triple oral therapy of metformin,\n      sulfonylurea, and pioglitazone 15 mg.\n\n      The study will enroll approximately 310 patients. Participants will be randomly assigned (by\n      chance, like flipping a coin) to one of the two treatment groups\u2014which will remain\n      undisclosed to the patient and study doctor during the study (unless there is an urgent\n      medical need):\n\n        -  Pioglitazone 15 mg + Metformin and sulfonylurea\n\n        -  Pioglitazone 30 mg + Metformin and sulfonylurea\n\n      All participants will be asked to take one pioglitazone tablet at the same time each day\n      throughout the study as well as continuing their previous dose of metformin and\n      sulfonylurea..\n\n      This multi-centre trial will be conducted in Korea. The overall time to participate in this\n      study is up to 25 weeks. Participants will make 4 visits to the hospital or\n      endocrinologist's office, and will be contacted by telephone 7 days after last dose of study\n      drug for a follow-up assessment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Institutional Review Board (IRB)-approved written informed consent form (ICF) must be\n             obtained from the patient or legally authorized representative prior to any trial\n             related procedure (including withdrawal of prohibited medication, if applicable)\n\n          2. Patients with a history of clinical diagnosis of established type 2 diabetes mellitus\n             defined by the ADA criteria 2012\n\n          3. Male or female between 18 and 80 years of age\n\n          4. Patients with stable triple oral therapy of metformin + sulfonylurea + pioglitazone\n             (ACTOS) 15 mg or ACTOSMET(Pioglitazone 15mg/Metformin 850mg) and sulfonylurea for at\n             least 12 weeks at the screening visit\n\n          5. Patients with HbA1c \u22657.0% at the screening visit\n\n          6. Patients with C-peptide \u22651.0 ng/mL at the screening visit\n\n          7. Females of childbearing potential who are sexually active must agree to use adequate\n             contraception, and can neither be pregnant nor lactating from screening throughout\n             the duration of the study, up to 60 days after the last dose of the study medication\n\n        Exclusion Criteria:\n\n          1. Patients with type 1 diabetes mellitus or secondary forms of diabetes\n\n          2. Patients who have been treated with insulin for \u22657 days within 3 months prior to the\n             screening visit\n\n          3. Patients with a history of bladder cancer or patients with active bladder cancer\n\n          4. Patients with a history of acute diabetic complications such as diabetic ketoacidosis\n\n          5. Patients with a history of acute or chronic metabolic acidosis, including diabetic\n             ketoacidosis\n\n          6. Patients with unstable or rapidly progressive diabetic retinopathy, nephropathy\n             (estimated glomerular filtration rate [eGFR] <60mL/min/1.73m2)\n\n          7. Patients with cardiac insufficiency (e.g., a myocardial infarction, a coronary\n             angioplasty or bypass graft, unstable angina, transient ischemic attacks, or a\n             documented cerebrovascular accident within 6 months prior to the screening visit)\n\n          8. Patients with cardiac failure or history of cardiac failure (New York Heart\n             Association [NYHA] Stages 3 to 4)\n\n          9. Patients with a serum alanine transaminase (ALT) level \u22652.5 times the upper limit of\n             normal (ULN), active liver disease, or jaundice\n\n         10. Patients taking concomitant gemfibrozil or other strong cytochrome P450 (CYP)2C8\n             inhibitors\n\n         11. Patients with a history of recurrent or severe hypoglycemia\n\n         12. Patients with a history of any hemoglobinopathy (such as hemolytic anemias or sickle\n             cell disease) that may affect determination of HbA1c\n\n         13. Patients with uninvestigated microscopic hematuria\n\n         14. Patients with genetic problems such as galactose intolerance, Lapp lactase\n             deficiency, or glucose-galactose malabsorption, since the study drug contains lactose\n\n         15. Patients with any other condition judged by the Investigator as unsuitable for the\n             study\n\n         16. Patients who have used any investigational or experimental drugs or devices within 60\n             days of the screening visit\n\n         17. Lactating or pregnant female. A positive pregnancy test before the first\n             administration of investigational medicinal product or breastfeeding\n\n         18. Male patients planning to father during clinical trial conduct or within 3 months\n             after the last planned dose of the IMP\n\n         19. Patients were previously enrolled into the current clinical trial\n\n         20. Prior to the start of the clinical trial the patient participated in the active\n             treatment phase of another clinical trial where a persisting pharmacodynamic effect\n             of the IMP of that clinical trial cannot be excluded (e.g., patient is well into a\n             treatment-free follow-up phase)\n\n         21. Patients are considered unable or unwilling to co-operate adequately, i.e., to follow\n             clinical trial procedures and Investigator instructions adequately (e.g., language\n             difficulties, etc.) or patients are anticipated not to be available for scheduled\n             clinical trial visits/procedures."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "310", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01972724", 
            "org_study_id": "PG-9999-301-KR", 
            "secondary_id": "U1111-1145-8222"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Pioglitazone 15 mg", 
                    "Pioglitazone 30 mg"
                ], 
                "description": "Pioglitazone tablets", 
                "intervention_name": "Pioglitazone", 
                "intervention_type": "Drug", 
                "other_name": "ACTOS"
            }, 
            {
                "arm_group_label": [
                    "Pioglitazone 15 mg", 
                    "Pioglitazone 30 mg"
                ], 
                "description": "Metformin tablets", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Pioglitazone 15 mg", 
                    "Pioglitazone 30 mg"
                ], 
                "description": "Sulfonylurea tablets", 
                "intervention_name": "Sulfonylurea", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pioglitazone", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Drug therapy", 
        "lastchanged_date": "October 24, 2013", 
        "link": {
            "description": "ACTOS\u00ae Package Insert", 
            "url": "http://general.takedapharm.com/content/file/pi.pdf?applicationcode=ab2d7112-8eb3-465a-8fda-35018a9eafb0&fileTypeCode=ACTOSPI"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chagwon", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Daejeon", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gwangju", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jeonju", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoungnam", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ulsan", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wonju", 
                        "country": "Korea, Republic of"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 24-Week, Randomized, Double-Blind, Phase IV Trial to Evaluate the Efficacy of Pioglitazone 30 mg in Patients With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy of Metformin, Sulfonylurea, and Pioglitazone 15 Mg (ADD Trial)", 
        "overall_contact": {
            "email": "medicalinformation@tpna.com", 
            "last_name": "Takeda Study Registration Call Center", 
            "phone": "800-778-2860"
        }, 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The change from Baseline in glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at Week 24.", 
            "measure": "Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01972724"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The change between the value of fasting serum glucose collected at Week 24 and fasting serum glucose collected at Baseline.", 
            "measure": "Change From Baseline in Fasting Plasma Glucose at Week 24", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Week 24"
        }, 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}